GGHC
TARS icon

Gilder Gagnon Howe & Co’s Tarsus Pharmaceuticals TARS Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-77,164
Closed -$3.13M – 262
2025
Q2 		$3.13M Sell
77,164
-339,647
-81% -$15.3M 0.03% 160
2025
Q1 		$21.4M Buy
416,811
+12,574
+3% +$622K 0.28% 80
2024
Q4 		$22.4M Buy
404,237
+397,190
+5,636% +$18M 0.24% 84
2024
Q3 		$232K Buy
+7,047
New +$198K ﹤0.01% 246

Other funds holding TARS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Gilder Gagnon Howe & Co's TARS Position: Q3 2025 in Review

Gilder Gagnon Howe & Co sold out of Tarsus Pharmaceuticals (TARS) in Q3 2025, closing a stake of 77,164 shares — an estimated $3.13M sold.

Gilder Gagnon Howe & Co first reported a position in TARS in Q3 2024 and held it in 4 quarters. The position peaked at $22.4M in Q4 2024. 220 funds tracked by Wall St. Rank hold TARS as of Q3 2025.

  • Gilder Gagnon Howe & Co reported no remaining Tarsus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 77,164 Tarsus Pharmaceuticals shares in Q3 2025, an estimated $3.13M.
  • Gilder Gagnon Howe & Co first reported a position in Tarsus Pharmaceuticals in Q3 2024 and held it in 4 quarters.
  • Gilder Gagnon Howe & Co's Tarsus Pharmaceuticals position peaked at $22.4M in Q4 2024.
  • 220 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2025.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2025, filed 14 Nov 2025.